On June 28th, Gelunhui reported that US genetic testing company illumina stated that it would record goodwill impairment expenses of USD 1.47 billion in the second quarter, which is related to the recently divested cancer diagnosis test manufacturer Grail. It may result in additional impairment charges of about USD 420 million for Grail's ongoing research and development intangible assets (IPR&D). However, the company added that no significant cash expenditures related to these impairments are expected in the future. In December last year, activist investor Carl Icahn said that Grail's unexpected spending and delayed testing progress also forced Illumina to record a total of US$4.7 billion in impairment losses. Regulatory filings submitted by Grail showed that the company expects to record goodwill impairment expenses of USD 888.9 million in the second quarter, and will conduct midterm impairment tests for goodwill and indefinite-lived intangible assets. As of March 31, Grail had USD 560 million in intellectual property and research and development intangible assets.
Illumina将在Q2计提与Grail相关的14.7亿美元商誉减值支出
illumina will record a goodwill impairment expense of $1.47 billion related to Grail in Q2.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.